Home Articles List Article Information
Afro-Egyptian Journal of Infectious and Endemic Diseases
Journal Archive
Volume Volume 12 (2022)
Volume Volume 11 (2021)
Volume Volume 10 (2020)
Volume Volume 9 (2019)
Volume Volume 8 (2018)
Volume Volume 7 (2017)
Volume Volume 6 (2016)
Volume Volume 5 (2015)
Volume Volume 4 (2014)
Volume Volume 3 (2013)
Volume Volume 2 (2012)
Volume Volume 1 (2011)
El-Folly, R., Ali, H., EL-Fouly, N. (2018). Assessment of Cancer Antigen 125 in Post-HCV Chronic Liver Disease and Hepatocellular Carcinoma Patients. Afro-Egyptian Journal of Infectious and Endemic Diseases, 8(2), 88-93. doi: 10.21608/aeji.2018.8741
Rania F El-Folly; Heba H Ali; Nevien F EL-Fouly. "Assessment of Cancer Antigen 125 in Post-HCV Chronic Liver Disease and Hepatocellular Carcinoma Patients". Afro-Egyptian Journal of Infectious and Endemic Diseases, 8, 2, 2018, 88-93. doi: 10.21608/aeji.2018.8741
El-Folly, R., Ali, H., EL-Fouly, N. (2018). 'Assessment of Cancer Antigen 125 in Post-HCV Chronic Liver Disease and Hepatocellular Carcinoma Patients', Afro-Egyptian Journal of Infectious and Endemic Diseases, 8(2), pp. 88-93. doi: 10.21608/aeji.2018.8741
El-Folly, R., Ali, H., EL-Fouly, N. Assessment of Cancer Antigen 125 in Post-HCV Chronic Liver Disease and Hepatocellular Carcinoma Patients. Afro-Egyptian Journal of Infectious and Endemic Diseases, 2018; 8(2): 88-93. doi: 10.21608/aeji.2018.8741

Assessment of Cancer Antigen 125 in Post-HCV Chronic Liver Disease and Hepatocellular Carcinoma Patients

Article 4, Volume 8, Issue 2, June 2018, Page 88-93  XML PDF (364.78 K)
Document Type: Original Article
DOI: 10.21608/aeji.2018.8741
Authors
Rania F El-Folly1; Heba H Ali2; Nevien F EL-Fouly3
1Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
3Tropical Medicine, Department of Health Research, National Center for Radiation Research and Technology, Atomic Energy Authority, Cairo, Egypt
Abstract
Background and study aim: Most of the morbidity and mortality of chronic liver diseases is due to its progression and complication of cirrhosis as ascites. The cancer antigen (CA) -125 is a high molecular mass glycoprotein produced both by ovarian cancer cells as well as by normal cells derived from coelomic epithelium. This study was conducted to assess the serum and/or ascitic fluid level of CA125 in HCV cirrhotic patients (decompensated or not) with or without Hepatocellular Carcinoma (HCC).
Patients and Methods: Group I: Session [CurrentTestPartID] post HCV liver cirrhosis cases; (A) 30 cases without ascites, (B) 30 cases with ascites. Group II: Session [CurrentTestPartID] HCC of post HCV liver cirrhosis cases; (C) 30 cases without ascites, (D) 30 cases with ascites. Serum and ascetic fluid level of CA-125 as well as serum AFP were assessed in all cases.
Results: Serum level of CA-125 between group A&B being higher in group B (P<0.01), however between groups C&D being higher in group D (P<0.01). There was a positive correlation between serum level of CA-125 and AFP level in group A and C (P>0.05). Regarding Group B and D, there was a positive correlation between serum level of CA-125 and each of AFP level (P>0.05) and ascitic level of CA-125 (P<0.01). Concerning the ascitic level of Ca 125, being higher in group D than B (P<0.01). Only AFP had a significant diagnostic performance (P<0.01) in differentiating HCC groups from non-HCC groups.
Conclusion: Elevated serum and ascetic level of CA125 in decompensated cirrhosis with or without HCC. AFP had a diagnostic performance in HCC diagnosis
Keywords
Hepatocellular carcinoma; Cancer Antigen 125; Post-HCV Chronic Liver Disease
Main Subjects
Hepatology
Statistics
Article View: 189
PDF Download: 247